GlassScriptPhysician profile
Ashok K Ammula
NPI 1356558894
$2,218.52
in general payments reported to CMS, 2019-2025
26 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $145 · 2021: $115 · 2022: $353 · 2023: $429 · 2024: $198 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $64.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.10 |
| Education | $64.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.52 | 2019-2023 | Lokelma |
| Amgen INC. | $193.52 | 2019-2025 | Tavneos, Parsabiv |
| Travere Therapeutics, INC. | $189.61 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.42 | 2021-2025 | |
| Vifor Pharma, INC. | $147.88 | 2019-2023 | Korsuva, Veltassa |
| Horizon Therapeutics Plc | $137.07 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $136.14 | 2024-2025 | |
| Nxstage Medical, INC. | $135.72 | 2023-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Otsuka America Pharmaceutical, INC. | $131.88 | 2019 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Opko Pharmaceuticals, LLC | $98.06 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $93.02 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $58.80 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $54.95 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $49.74 | 2020-2023 | Acthar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $46.98 | 2019-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $35.50 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $32.65 | 2022-2023 | Lupkynis |
| Daiichi Sankyo INC. | $24.58 | 2019 | |
| Glaxosmithkline, LLC. | $19.46 | 2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.93 | 2025 | Jardiance |
| Ardelyx, INC. | $15.48 | 2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $15.43 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.12 | 2019 | |
| Genentech USA, INC. | $10.82 | 2019 | |
| Outset Medical INC | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Ammula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.